The question „how long do you have to wait for it to work?” actually encompasses three distinct issues. The first concerns how quickly any measurable changes appear after starting the use of an NAD+ precursor, which is the onset of action. The second concerns how long the effects of a single dose or a period of use can last after taking the product or stopping it, which is the duration. The third concerns how long the product remains stable or usable after reconstitution before degradation, which is the shelf life. In everyday discussions, these questions are often lumped together, even though the evidence behind each is different. In this guide, we discuss them separately.
Onset of action: how long do you have to wait for any effect?
It is important to distinguish between two different concepts: how quickly metabolites related to NAD+ change in the blood after taking a dose, and how quickly a person can notice a subjective effect, such as a change in energy levels, mood, or another perceived parameter.
Changes in biomarkers can appear relatively quickly, although they represent only part of the whole picture. Pharmacokinetic studies show that even a single oral dose of an NAD+ precursor can cause measurable changes in NAD+-related metabolites in the blood within a few hours. One study evaluated single doses of 100 mg, 300 mg, and 1000 mg of nicotinamide riboside and found a dose-dependent increase in the corresponding metabolites after just a single administration [1]. In this narrow biochemical sense, the onset of action occurs within hours as the compound is absorbed and enters pathways related to NAD+ metabolism.
Sustained increases require significantly more time. The effect of a single dose on circulating metabolites is transient and does not represent a permanent shift in baseline NAD+ levels. In a Phase I pharmacokinetic study involving multiple daily administrations, blood NAD+ levels increased gradually and reached a plateau after approximately two weeks of regular daily use. NAD+ measurements in brain tissue changed more slowly, with measurable increases recorded after about four weeks of daily use [2]. This distinction is important because a single dose may alter blood biochemical parameters within a few hours, whereas the sustained elevation observed in longer clinical trials developed over approximately two weeks in the blood and about four weeks in brain tissue.
The subjective onset of action is much less clearly defined. Published clinical trials generally were not designed to determine the exact moment when someone first notices changes such as increased energy, improved sleep, better concentration, or a change in mood. Most studies on NAD+ precursors evaluated functional outcomes at predetermined time points, such as 6, 8, 12, or 60 days, rather than recording precisely when the effect was first noticed. As a result, claims that people typically „feel a difference after a few days” cannot currently be precisely confirmed or rejected based on published clinical trial data. This remains a gap in the evidence.
Duration: How long do the effects of a single dose last?
The pharmacokinetic results described above show that a single dose of the NAD+ precursor causes a transient increase in circulating metabolites, followed by a gradual decrease over the subsequent hours [1]. A single administration does not cause a sustained change in NAD+ levels. This helps explain why major clinical trials on nicotinamide riboside or NMN analyzing sustained changes in NAD+-related biomarkers typically used multiple daily administrations rather than a single dose.
In the case of the increase achieved through regular daily use, the same pharmacokinetic study showed that after supplementation ceased, blood NAD+ levels declined at a similarly gradual rate [2]. In other words, the elevated levels did not return to baseline immediately. They gradually approached it over a period roughly comparable to the time required for the initial increase, which is about two weeks.
The rate of increase may also vary slightly over time, even with continued daily use. In one 8-week study, the increase in whole-blood NAD+ levels was slightly lower in week 8 than in week 2 within the same dosing groups. For example, in one group, an increase of 51% was observed after two weeks compared to 48% after eight weeks, whereas in another group, the increase was 142% after two weeks and 139% after eight weeks [3]. These differences were relatively small, but they show that the relationship between duration of use and NAD+ concentration does not necessarily follow a steadily increasing linear trend.
How do the onset of action and duration differ depending on the form (oral, injection, and intravenous)?
The information described above regarding onset of action and duration of effect is derived primarily from studies of oral NR and NMN. These forms have been studied much more thoroughly in this regard than other routes of administration. The evidence regarding other delivery methods is more limited.
Intravenous NAD+ delivers the compound directly into the bloodstream, bypassing gastrointestinal absorption. Therefore, faster systemic exposure can be expected than with oral administration. However, no direct head-to-head studies have been established comparing the onset of action of intravenous NAD+ with oral NAD precursors. Published studies on intravenous NAD+ generally used short, defined cycles rather than single isolated administrations. Examples include seven consecutive daily administrations in one heart failure study and four consecutive days of administration in a retrospective review of commercial IV therapies [4,5]. Such study designs are consistent with the broader observation that repeated exposure has most commonly been utilized when analyzing sustained biological changes.
Subcutaneous or intramuscular injections have not been studied in controlled clinical trials with the same level of detail regarding the onset of action and duration of action as oral or intravenous forms. The evidence regarding these routes of administration is therefore insufficient to establish a reliable pattern of onset or duration of action.
Sublingual and liposomal forms also lack dedicated human studies directly comparing their onset of action and duration with standard oral capsules. Therefore, it cannot be reliably stated that they work faster, slower, or for a different duration than standard oral forms.
Because the amount of evidence varies depending on the route of administration, approximately two weeks to achieve a sustained increase in the blood and approximately four weeks in brain tissue is the best-described time frame in the literature discussed. However, it should be emphasized that these values come specifically from studies on oral precursors [2] and should not be automatically extrapolated to other routes of administration.
How long does NAD+ remain measurable in the body?
This question partially overlaps with the issue of duration, but it is worth discussing separately. After stopping regular use of the NAD+ precursor, the elevated NAD+ level in the blood does not appear to disappear immediately.
The pharmacokinetic studies discussed above suggest that the return toward baseline values occurs gradually, over a period roughly comparable to the time of the initial increase, which is about two weeks [2]. This means that changes in measurable NAD+ levels may persist for some time after administration is stopped, rather than fading within a few hours.
The timing of laboratory tests can therefore affect the interpretation of results. Measuring NAD+ too early after starting supplementation, before the approximately two-week plateau described in the study, may not reflect the sustained levels observed later. Similarly, a measurement taken shortly after discontinuation may still show a residual increase before levels gradually return toward baseline values.
These observations pertain to biomarker measurements and should not be interpreted as evidence that subjective or clinical effects persist for the same duration.
Storage and shelf life after reconstitution — separate from the question „how long does it work?”
Storage time is a different issue than the biological onset of action or its duration. The question „how long can NAD+ be stored in the refrigerator?” concerns the physical and chemical stability of the prepared product, not how long its biological effects last after administration.
For injectable NAD+ reconstituted from lyophilized, i.e., freeze-dried powder, general pharmaceutical compounding principles are sometimes used to estimate post-preparation storage periods. Depending on the compound, formulation, container, sterility conditions, and available stability data, refrigerated preparations after reconstitution may sometimes have a shelf life measured in days or weeks [6].
Based on the discussed evidence, however, it is not possible to establish a single validated, universal post-reconstitution shelf-life specific to injectable NAD+. Therefore, general ranges applied to other compounded or reconstituted preparations should not be presented as specifically confirmed for NAD+. Priority should be given to the information on the specific product label, validated stability studies, or recommendations from a suitably qualified pharmacy or manufacturer.
Visible turbidity, discoloration, or the presence of particles may indicate that the solution should not be used, however, the absence of visible changes does not confirm that the product remains chemically stable, sterile, or suitable for administration. Some degradation products or microbiological contaminants may be invisible.
Oral capsules and tablets are subject to a different storage schedule because they do not require reconstitution. Their shelf life is typically determined by the product's expiration date and storage conditions, rather than by post-reconstitution stability.
Limitations of current evidence
- The subjective onset of action, meaning the moment when an individual first notices a perceptible effect rather than a change in a laboratory biomarker, has not been systematically monitored in published clinical trials. This remains an evidence gap rather than a clearly established time frame.
- An approximately two-week duration of sustained elevation in the blood and four weeks in brain tissue comes from a single Phase I pharmacokinetic study with a relatively small number of participants [2]. Additional independent studies would increase confidence in these specific estimates.
- Evidence describing the onset of action and duration of injectable, intravenous, sublingual, and liposomal forms is much less developed than the evidence for standard oral NR and NMN preparations, making direct comparisons between routes of administration difficult.
- Estimates of the shelf life of NAD+ after reconstitution based on general principles of pharmaceutical compounding should not be interpreted as validated stability data specific to NAD+ [6].
- Changes in biomarkers do not necessarily correspond to subjective effects or clinically meaningful outcomes, and the duration of elevated NAD+ levels should not be automatically equated with the duration of health benefits.
Disclaimer
The article is for educational and scientific-informational purposes only. It does not constitute medical advice, a diagnosis, therapeutic recommendations, information regarding dosage, or recommendations for the use of NAD+, NAD+ precursors, or injectable products.
NAD+ and its precursors should not be presented as FDA- or EMA-approved methods for preventing, treating, or curing diseases, unless referring to a specific approved medicinal product and indication. Changes in NAD+-related biomarkers do not in themselves constitute proof of clinical benefit.
Before starting a new supplement or injectable product, you should consult a qualified healthcare professional or pharmacist. Decisions regarding product storage, handling, and shelf life should be based on validated information specific to the product or appropriate pharmaceutical recommendations, rather than generalized post-reconstitution timeframes.
References
[1] Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications, 7, 12948. https://doi.org/10.1038/ncomms12948
[2] Berven, H., Svensen, M., Eikeland, H., Tvedten, N., Sheard, E. V., Amdahl Af Geijerstam, S., Søgnen, M., McCann, A., Arnsten, L., Årseth, O., Skjeie, V., Hjellbrekke, A., Skeie, G.-O., Torres Cleuren, Y. N., Nido, G. S., Haugarvoll, K., Riemer, F., Tzoulis, C., & Dölle, C. (2026). The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. iScience, 29(3), 114764. https://doi.org/10.1016/j.isci.2026.114764
[3] Conze, D., Brenner, C., & Kruger, C. L. (2019). Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports, 9, 9772. https://doi.org/10.1038/s41598-019-46120-z
[4] American Journal of Cardiovascular Drugs. (2026). Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: A randomized, placebo-controlled trial. American Journal of Cardiovascular Drugs. https://pmc.ncbi.nlm.nih.gov/articles/PMC12779688/
[5] Reyna, K., Heinzen, G., Patel, N., Ritter, M., Siojo, A., Legere, H., & Pojednic, R. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): A retrospective tolerability pilot study in a real-world setting. Frontiers in Aging, 7, 1652582. https://doi.org/10.3389/fragi.2026.1652582
[6] Empower Pharmacy. (2025). How to prepare a lyophilized powder for injection. Empower Pharmacy Patient Resources. https://www.empowerpharmacy.com/compound-medication/medication-instructions/how-to-prepare-lyophilized-powder-for-injection/